Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463640 | 0.95 | FAAH (0.53) | FAAHPIK3CAKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL2456865 | 0.95 | FAAH (0.53) | FAAHPIK3CAKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL2459086 | 0.90 | FAAH (0.57) | FAAHKDM4ENPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL2458662 | 0.89 | FAAH (0.60) | FAAHKDM4ENPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL2456948 | 0.89 | FAAH (0.62) | FAAHKDM4ENPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL2457322 | 0.88 | FAAH (0.64) | FAAHKDM4ENPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL2458520 | 0.86 | FAAH (0.53) | FAAHIGF1RTNFULK1GRM4 | |
| SCHEMBL2531475 | 0.85 | FAAH (0.56) | FAAHTNF | |
| SCHEMBL2460834 | 0.82 | FAAH (0.54) | FAAHIGF1RTNFULK1GRM4 | |
| SCHEMBL2456460 | 0.82 | FAAH (0.52) | FAAHKDM4ENPC1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | claimed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | FAAH, FAAH2, CNR2 | FAAH 1/4885ABL1 4784/4885BCR 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.